37,393 shares of Myriad Genetics, Inc. (NASDAQ:MYGN) purchased by HRT Financial LP

HRT Financial LP acquired a new stake in Myriad Genetics, Inc. (NASDAQ: MYGN – Get Rating) in the fourth quarter, according to its latest Form 13F filed with the Securities and Exchange Commission. The institutional investor acquired 37,393 shares of the company, valued at approximately $542,000.

Other institutional investors and hedge funds have also recently increased or decreased their stakes in the company. The Royal Bank of Canada increased its position in Myriad Genetics by 29.0% in the third quarter. The Royal Bank of Canada now owns 2,339 shares of the company worth $44,000 after buying another 526 shares during the most recent quarter. Point72 Hong Kong Ltd strengthened its position in Myriad Genetics by 722.8% in the second quarter. Point72 Hong Kong Ltd now owns 3,217 shares of the company valued at $58,000 after purchasing an additional 2,826 shares during the latest quarter. US Bancorp DE increased its position in Myriad Genetics by 14.6% in the first quarter. US Bancorp DE now owns 4,243 shares of the company valued at $108,000 after buying another 541 shares during the most recent quarter. Captrust Financial Advisors increased its position in Myriad Genetics by 103.2% in the first quarter. Captrust Financial Advisors now owns 5,083 shares of the company valued at $128,000 after purchasing an additional 2,581 shares during the most recent quarter. Finally, Exchange Traded Concepts LLC increased its position in Myriad Genetics by 42.7% in the fourth quarter. Exchange Traded Concepts LLC now owns 7,072 shares of the company valued at $103,000 after purchasing an additional 2,116 shares during the most recent quarter. 99.08% of the stock is owned by hedge funds and other institutional investors.

Internal activity

In other news, COO Nicole Lambert sold 6,433 shares of Myriad Genetics in a deal on Monday, March 27. The stock sold at an average price of $23.48, for a total transaction of $151,046.84. As a result of the sale, the chief operating officer now owns 240,506 shares of the company, valued at $5,647,080.88. The transaction was disclosed in a filing with the SEC, accessible via this link. In other news, director Daniel K. Spiegelman sold 8,638 shares of Myriad Genetics in a deal on Friday, June 2. The stock sold at an average price of $23.01, for a total transaction of $198,760.38. As a result of the sale, the director now owns 40,493 shares of the company, valued at $931,743.93. The transaction was disclosed in a filing with the SEC, accessible via this link. Additionally, COO Nicole Lambert sold 6,433 shares of Myriad Genetics in a transaction that took place on Monday, March 27. The stock sold at an average price of $23.48, for a total transaction of $151,046.84. As a result of the transaction, the chief operating officer now owns 240,506 shares of the company, valued at $5,647,080.88. Disclosure for this sale is available here. Corporate insiders own 2.00% of the company’s shares.

Myriad Genetics trades up 1.4%

MYGN opened Friday at $23.43. Myriad Genetics, Inc. has a fifty-two week low of $13.92 and a fifty-two week high of $28.18. The company’s 50-day moving average price is $21.52, and its 200-day moving average price is $20.05.

Myriad Genetics (NASDAQ: MYGN – Get Rating) last released its quarterly earnings data on Wednesday, May 3. The company reported ($0.21) earnings per share for the quarter, missing the ($0.02) consensus estimate of ($0.19). The company reported revenue of $181.20 million for the quarter, compared with analyst estimates of $171.56 million. Myriad Genetics had a negative return on equity of 7.42% and a negative net margin of 21.05%. Myriad Genetics revenue increased 9.9% over the same quarter last year. In the same quarter last year, the company earned ($0.14) EPS. Equity analysts expect Myriad Genetics, Inc. to post -0.63 EPS for the current fiscal year.

Changes to Analyst Ratings

MYGN has been the subject of several recent analyst reports. Goldman Sachs Group upgraded shares of Myriad Genetics from a “sell” rating to a “buy” rating and raised its price target for the company from $18.00 to $25.00 in a research note on Tuesday, May 23 . StockNews.com began coverage of Myriad Genetics stock in a research note on Thursday, May 18. They have issued a “hold” rating on the stock. Raymond James raised Myriad Genetics’ stock price target from $25.00 to $27.00 and gave the company an “outperform” rating in a research note on Friday, March 3. Ultimately, Stephens raised Myriad Genetics’ stock price target from $17.00 to $24.00 and gave the company an “equal weight” score in a research note on Monday, March 6. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating for the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $26.60.

About a myriad of genetics

(Get Rating)

Myriad Genetics, Inc is committed to the discovery, development and commercialization of transformative molecular diagnostic tests. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of tests designed to assess an individual’s risk of developing disease later in life.

Featured Stories

Institutional Ownership by Quarter for Myriad Genetics (NASDAQ:MYGN)

This instant news alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Before you consider Myriad Genetics, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated and best-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are whispering to their clients to buy now before the broader market catches on…and Myriad Genetics wasn’t on the list.

While Myriad Genetics currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

View the five titles here

10 "Recession proof" Stocks that will thrive in any market hedge

#shares #Myriad #Genetics #NASDAQMYGN #purchased #HRT #Financial

Leave a Comment